Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 6/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5107646 | 0.98 | SMN1; SMN2 (0.45) | SMN1; SMN2TDP1MBTD1L3MBTL3RORC | |
| SCHEMBL5107703 | 0.92 | SMN1; SMN2 (0.40) | SMN1; SMN2TDP1MBTD1L3MBTL3RORC | |
| Hydrochloric Acid SCHEMBL5100769 | 0.91 | MBTD1 (0.40) | SMN1; SMN2TDP1MBTD1L3MBTL3RORC | |
| SCHEMBL5094225 | 0.88 | SIRT2 (0.42) | SMN1; SMN2TDP1MBTD1L3MBTL3SIRT2 | |
| SCHEMBL14458401 | 0.86 | DRD2 (0.43) | SMN1; SMN2TDP1MBTD1L3MBTL3RORC | |
| SCHEMBL5621353 | 0.86 | DRD2 (0.43) | SMN1; SMN2TDP1MBTD1L3MBTL3RORC | |
| SCHEMBL5097653 | 0.85 | MBTD1 (0.40) | SMN1; SMN2TDP1MBTD1L3MBTL3RORC | |
| SCHEMBL14410080 | 0.85 | MBTD1 (0.40) | SMN1; SMN2TDP1MBTD1L3MBTL3RORC | |
| Hydrochloric Acid SCHEMBL5107647 | 0.84 | MBTD1 (0.39) | SMN1; SMN2TDP1MBTD1L3MBTL3RORC | |
| Trifluoroacetic Acid SCHEMBL5107729 | 0.81 | BRD4 (0.38) | SIRT2SIRT1SIGMAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371754-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2008-05-13 | — | — | US | claimed |
| EP-1496907-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2007-09-19 | — | — | EP | claimed |
| US-20050227988-A1 | compounds capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases; gliomas, meningomas, cancers, Hodgkin's disease, retinal vascularization; core structure that comprises a benzazocine moiety | MERCK SHARP & DOHME CORP. | 2005-10-13 | — | — | US | claimed |
| US-7371754-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1496907-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1496907-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20050227988-A1 | compounds capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases; gliomas, meningomas, cancers, Hodgkin's disease, retinal vascularization; core structure that comprises a benzazocine moiety | MERCK SHARP & DOHME CORP. | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227988-A1 | compounds capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases; gliomas, meningomas, cancers, Hodgkin's disease, retinal vascularization; core structure that comprises a benzazocine moiety | KDR, RET, FLT1 | SMN1; SMN2 3886/4885TDP1 2934/4885MBTD1 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.